Core Insights - Roche, in collaboration with KlinRisk, Inc., has received the CE-mark for the first AI-based risk stratification tool for assessing progressive decline in kidney function, marking a significant advancement in chronic kidney disease (CKD) management [1][9] - The new Chronic Kidney Disease algorithm panel, which includes the Kidney Klinrisk Algorithm and the established Kidney KFRE Algorithm, aims to support care across all stages of CKD, affecting over 700 million people globally [2][9] - The AI-based solution is designed to assist healthcare professionals in making informed decisions and managing patients' kidney function proactively, particularly in early and asymptomatic stages of CKD [4][6] Company Overview - Roche is a leading biotechnology company and global leader in in-vitro diagnostics, committed to developing innovative medicines and diagnostics to improve patient care [13] - The navify® Algorithm Suite, which includes the new CKD algorithm panel, integrates seamlessly with existing hospital systems, providing clinicians with a single point of access for ordering and viewing algorithm results [5][11] - Roche's digital health solutions are part of a broader strategy to address the growing global burden of chronic kidney disease and enhance operational and clinical excellence in healthcare [5][12] Industry Context - Chronic kidney disease is a progressive condition that affects more than 700 million people worldwide and is linked to other chronic conditions such as diabetes and hypertension [2][8] - The rising incidence of CKD is driven by increasing cases of diabetes, hypertension, and obesity, making it a significant healthcare cost driver, representing up to 2-3% of annual healthcare budgets [9][10] - Early diagnosis and appropriate treatment of CKD can delay or prevent kidney function decline, thereby reducing cardiovascular risk and related healthcare costs [2][4]

Company Overview - Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines targeting hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA), and other diseases driven by dysregulated aldosterone [3] - The company's initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor aimed at treating cardiorenal conditions affected by dysregulated aldosterone [3] Financial Results Announcement - Mineralys Therapeutics will report its financial results for the first quarter ended March 31, 2025, after the financial markets close on May 12, 2025 [1] - A live conference call will take place on May 12 at 4:30 p.m. ET, with details provided for both domestic and international participants [2]